BRIEF-Repros Therapeutics jumps in premarket after testosterone drug hits main goals of study

NEW YORK, March 28 (Reuters) - Repros Therapeutics Inc : * Jumps 75.3 to $16 in premarket after testosterone drug hits main goals of study
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.